Eighty-six percent of U.S. clinical trials are delayed because of lack of enrollment, creating a massive bottleneck in disease research and drug development — and costing the life science system billions of dollars. Even more distressing: Less than 5 percent of U.S. patients ever take part in a potentially life-changing clinical trial due to opaque practices and antiquated systems.
Power was built with a mission to modernize clinical trial access. The company believes groundbreaking therapeutic options should be available to all patients, regardless of geographical location, ethnicity, or socioeconomic background.
